Depot bromperidol decanoate for schizophrenia (Q24246708)

Europe PubMed Central

title

Depot bromperidol decanoate for schizophrenia (English)

0 references

0 references

Clive E Adams

1

C E

Adams

1 reference

26 October 2023

Anthony David

2

A

David

1 reference

26 October 2023

Seema N Quraishi

series ordinal

3

author given names

S N

author last names

Quraishi

1 reference

26 October 2023

D Wong

author given names

D

author last names

Wong

series ordinal

1

1 reference

Cochrane Database of Systematic Reviews

26 October 2023

publication date

19 July 2004

0 references

published in

0 references

cites work

Long-term depot antipsychotics. A risk-benefit assessment

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001719.PUB2

Improving the quality of reporting of randomized controlled trials. The CONSORT statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001719.PUB2

Statistics notes. Trials randomised in clusters

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001719.PUB2

The unit of analysis error in studies about physicians' patient care behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001719.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001719.PUB2

Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001719.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001719.PUB2

Outpatient maintenance of chronic schizophrenic patients with long-acting fluphenazine: double-blind placebo trial. Report to the Medical Research Council Committee on Clinical Trials in Psychiatry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001719.PUB2

Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001719.PUB2

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001719.PUB2

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001719.PUB2

Assessing the quality of randomization from reports of controlled trials published in obstetrics and gynecology journals

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001719.PUB2

Cost-effectiveness comparisons using "real world" randomized trials: the case of new antidepressant drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001719.PUB2

Guidelines for depot antipsychotic treatment in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001719.PUB2

No relationship between Taq1 a polymorphism of dopamine D(2) receptor gene and extrapyramidal adverse effects of selective dopamine D(2) antagonists, bromperidol, and nemonapride in schizophrenia: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001719.PUB2

7 January 2021

A Double-blind Comparison of Bromperidol and Haloperidol in Newly Admitted Schizophrenic Patients

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001719.PUB2

7 January 2021

No effect of the anticholinergic drugs trihexyphenidyl and biperiden on the plasma concentrations of bromperidol and its reduced metabolite

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001719.PUB2

7 January 2021

Increased plasma concentrations of bromperidol and its reduced metabolite with levomepromazine, but not with thioridazine

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001719.PUB2

7 January 2021

Do schizophrenics well adapted in the community need neuroleptics? A depot neuroleptic withdrawal study

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001719.PUB2

7 January 2021

Clinical evaluation of bromperidol versus haloperidol in psychotic patients

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001719.PUB2

7 January 2021

Long-term depot maintenance of chronic schizophrenic out-patients: the seven year follow-up of the Medical Research Council fluphenazine/placebo trial I. Course of illness, stability of diagnosis, and the role of a special maintenance clinic

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001719.PUB2

7 January 2021

10.1002/14651858.CD001719.PUB2

Identifiers

DOI

0 references

Fatcat ID

release_ugm6xk6tczcttfyu3ut7qjqffe

0 references